Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Opko Health Inc (OPK)

Opko Health Inc (OPK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Opko Health Inc 4400 BISCAYNE BLVD. MIAMI FL 33137 USA

P: 305-575-4100

Description:

OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.

Key Statistics

Overview:

Market Capitalization, $K 1,792,411
Shares Outstanding, K 681,525
Annual Sales, $ 1,775 M
Annual Net Income, $ -30,140 K
Last Quarter Sales, $ 329,220 K
Last Quarter Net Income, $ -55,430 K
60-Month Beta 1.87
% of Insider Shareholders 40.97%
% of Institutional Shareholders 27.83%
Float, K 402,304
% Float 59.03%
Short Volume Ratio 0.46

Growth:

1-Year Return -37.97%
3-Year Return 11.44%
5-Year Return -58.78%
5-Year Revenue Growth 45.27%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.08 on 05/09/22
Next Earnings Date 08/04/22
Earnings Per Share ttm -0.18
EPS Growth vs. Prev Qtr 27.27%
EPS Growth vs. Prev Year -260.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

OPK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -6.86%
Return-on-Assets % -4.89%
Profit Margin % -1.70
Net Margin % -49.93
Debt/Equity 0.13
Price/Sales 0.97
Price/Cash Flow 34.89
Price/Book 1.07
Book Value/Share 2.37
Interest Coverage -0.26
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar